ABACUS MEDICINE A/S: Financial statements 2015
CVR: 28111576
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
ABACUS MEDICINE A/S (CVR 28111576) has filed annual accounts for 2015. In 2015, the company reported revenue of DKK 835,482,000 and a net result of DKK 17,815,000 compared with DKK 13,224,000 the year before. That is an increase of 33.6% compared with the year before. The profit margin was 2.1%. Equity in the 2015 report amounted to DKK 61,663,000. The solvency ratio was 34.3%. The company had 46 employees in the financial year.
- Revenue
- DKK 835,482,000
- Gross Profit
- DKK 61,823,000
- Profit/Loss
- DKK 17,815,000
- Equity
- DKK 61,663,000
- Total Assets
- DKK 179,823,000
- Employees
- 46
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | 835.5 mio. | 61.8 mio. | 17.8 mio. | 61.7 mio. | 46 |
| 2014 | 625.2 mio. | 56.4 mio. | 13.2 mio. | 24.4 mio. | 39 |
| 2013 | 489.5 mio. | 35.7 mio. | 5.7 mio. | 6.1 mio. | 40 |
Official annual report
How creditworthy is ABACUS MEDICINE A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
ABACUS MEDICINE A/S has published its annual report for 2014. Revenue came to DKK 625,228,000, and the net result was DKK 13,224,000.
About ABACUS MEDICINE A/S
ABACUS MEDICINE A/S is a Danish company of the type Aktieselskab based in København V, founded in 2004. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ABACUS MEDICINE ApS. The management consists of Flemming Wagner. The board consists of Jens Albert Harsaae (chair), Alette Margaretha Verbeek, Anders Kunze Bønding and Flemming Wagner. The company is owned by Wagner Family Holding ApS and CHR. AUGUSTINUS FABRIKKER AKTIESELSKAB. The company has 388 employees (2026). In 2025, the company reported revenue of EUR 1,817,637,000 and a net result of EUR 7,779,000 compared with EUR 17,621,000 the year before. Equity in the 2025 report amounted to EUR 98,523,000.